CorMedix Has Entered Into A Multi-Year Commercial Supply Contract With A Global Healthcare Company For The Supply Of DefenCath To Its Facilities In The U.S.
Portfolio Pulse from Benzinga Newsdesk
CorMedix Inc. has signed a multi-year commercial supply contract with a global healthcare company to supply DefenCath to US facilities. The product targets up to 4,000 patients and shipments are expected to begin in Q4.
September 09, 2024 | 2:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CorMedix Inc. has entered a multi-year supply contract for DefenCath with a global healthcare company, targeting up to 4,000 patients in the US. This could boost revenues and market presence.
The multi-year contract with a global healthcare company for DefenCath is significant for CorMedix as it expands its market reach and targets a substantial patient base. This is likely to positively impact revenues and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100